This publication keeps prescribing the same medicine to India: do not try to invent the modality — wait until someone proves it, then industrialise the proven one better and cheaper than the inventor can be bothered to. Second-mover, not first. Engineering, not discovery. It is the doctrine behind the CAR-T essay and the GLP-1 essay and half the others. The antibody-drug conjugate is the essay where that doctrine gets tested against reality — because the ADC is the purest second-mover modality medicine has ever produced, the hottest deal class in pharma, and the one where the second-mover playbook was run at enormous scale and won decisively. Not by India. By China. While India, which owns exactly the antibody and biosimilar base the modality is built on, shipped a single biosimilar and watched a neighbour bank tens of billions of dollars from Western pharma playing India's own game. This is the mirror the doctrine has to look into. It says second-mover is not a birthright. It is a race, and in ADCs India did not show up.
The armed antibody, and why pharma is at war over it
Start with what an ADC is, because its structure is why it became the second-mover's dream. An antibody-drug conjugate is three parts bolted together: an antibody that finds a specific marker on a cancer cell, a chemical linker, and a highly toxic payload — a poison far too dangerous to give on its own. The antibody is the guidance system; the payload is the warhead; the linker holds the warhead inert until it reaches the target. An armed antibody. A smart bomb for a tumour. It delivers a cell-killing dose precisely where it is wanted and, ideally, nowhere else.
The class arrived properly with Enhertu — trastuzumab deruxtecan, from Daiichi Sankyo and AstraZeneca — first approved in December 2019, and it did not merely work; it redrew treatment maps, turning cancers that were "HER2-negative" into "HER2-low" and treatable, because a smart bomb needs only a little target to home in on. The money followed the biology. In March 2023, Pfizer agreed to buy Seagen, the company that pioneered the modality, for about $43 billion — the largest biopharma acquisition in years, completed that December. When a major pays forty-three billion dollars to own a modality rather than a molecule, the modality has become the prize. ADCs are now the most contested territory in oncology.
The perfect second-mover modality
Here is why the ADC is the second-mover's dream, and why it should have been India's essay to write. Almost nothing about a modern ADC is de novo invention. The targets are already validated — HER2 and TROP2 were proven by earlier antibodies and earlier drugs; you are aiming at a marker everyone already knows matters. The payload classes are known chemistry. The linker science is published and iterated. What decides who wins is not the discovery of a new target but the engineering — a better linker that stays inert in the blood and releases cleanly in the tumour, a better payload, a better ratio of warheads per antibody, a better manufacturing process. It is optimization of a proven thing, not invention of a new one.
That is the exact shape of the doctrine this publication keeps handing India: let someone else retire the discovery risk, then win on engineering and cost. The ADC is that doctrine crystallised into a modality. Whoever can fast-follow a validated target with better linker-payload engineering, at lower cost, at speed, captures the value. The binary — does drugging this target work? — was answered by the pioneers. What remained was a race any disciplined, engineering-heavy, cost-competitive ecosystem could enter. India is a disciplined, engineering-heavy, cost-competitive ecosystem with the world's deepest antibody-biosimilar base. On paper, this was India's race.
China ran it.
China ran India's playbook, at scale, and won
The last three years of ADC dealmaking are one of the most striking geography rotations in pharma, and they are Chinese. In December 2023, Bristol Myers Squibb agreed to pay SystImmune and its parent Baili up to $8.4 billion — eight hundred million dollars of it upfront — for BL-B01D1, a bispecific ADC hitting two targets at once, developed in China. Merck signed a series of ADC deals with Kelun-Biotech across 2022 and 2023 whose combined ceilings run past nine billion dollars. BioNTech licensed ADCs from DualityBio; AstraZeneca licensed a GPRC5D ADC from LaNova. And these named deals are the visible peaks of a systematic wave: China-origin candidates were roughly forty per cent of all ADC out-licensing deals in 2023, and by 2024 ADCs made up more than half — around nineteen billion of thirty-three billion dollars — of the total value China's biotech sector out-licensed in oncology.
A necessary honesty about those numbers: they are "biobucks" — deal ceilings that assume every milestone is hit — not cash in the bank, and the reflexive discount every reader of this layer applies should be applied here too. But even discounted to the upfronts, the pattern is unambiguous and the direction is one-way: the most credible sellers of the hottest oncology modality in the world are increasingly Chinese, and the buyers are the Western majors staring down their patent cliffs.
Why China and not India is not a mystery, and it is not about better biology. It is the same four-ingredient circuit that lets China win the platform-output layer generally, applied to ADCs. China's drug regulator cut clinical-trial approval times from around five hundred days to under ninety, and proposed a thirty-working-day fast-track in 2025, so a Chinese ADC reaches first-in-human faster than a Western one clears its paperwork. Dense biotech clusters in Shanghai and Suzhou put roughly a quarter of the world's ADC-focused companies in one country. The state funded domestic payload chemistry to cut reliance on imported toxins. Cheap, fast, clustered, capitalised — the fast-follower's dream conditions, aimed at exactly the fast-follower's modality. China did not invent the ADC. It industrialised the proven one, better and faster and cheaper than the inventors bothered to. That sentence is this publication's entire doctrine. China wrote it in ADCs.
The mirror
So look directly into the mirror, because the discomfort is the point. Everything the doctrine prescribes to India — second-mover into a validated modality, engineering over invention, speed and cost as the weapons — China executed in ADCs while India was not meaningfully in the room. And this is not the usual, forgivable story of India ceding the frontier of discovery to richer ecosystems. India was supposed to be good at this part. The ADC is not the first-mover's game India rightly sits out; it is the second-mover's game the whole thesis says India should win. China beat India at India's own strategy, on the single modality most suited to it, for tens of billions of dollars.
The lesson is not that India cannot play. It is that the doctrine only pays if you actually run it — the ingredients have to be assembled, the regulator has to be fast, the clusters have to exist, the capital has to show up — and on ADCs, India assembled none of it in time. Second-mover advantage is not a property of being poor and talented. It is a race you enter or forfeit. India forfeited this one.
Where India actually is: two narrow doors
Strip the wishful thinking away and India has exactly two real positions in ADCs, both genuine, both narrow, both trailing.
The first is the biosimilar door, and India got there first. In 2021, Zydus launched Ujvira — a biosimilar of Kadcyla, trastuzumab emtansine — credibly the world's first ADC biosimilar. That is not a small thing; it is a genuine India-first in a hard modality, and it points at the one ADC game India's machine is built to win. As the pioneering ADCs age off patent, India's biosimilar industry — the same industry that made it the world's generic-drug shop — can make ADC biosimilars at Indian cost, for the Indian market and the wave-one world, exactly as it is doing with semaglutide. This is the GLP-1 doctrine applied to ADCs: not the deal-value war, which is lost, but the make-it-affordable war, which is still open.
The second is the picks-and-shovels door. ADC manufacturing is a genuine specialized bottleneck — handling payloads too toxic for ordinary facilities, sterile conjugation of antibody to warhead, exacting linker chemistry — and fewer than a third of ADC innovators can do all of it in-house. It is a real moat, of the same shape as the peptide-synthesis moat in GLP-1. India is entering it: Syngene stood up a dedicated bioconjugation suite in Bengaluru in late 2025, and Cohance markets integrated ADC contract services. But "entering" is the honest verb. China's WuXi is years ahead as the world's ADC contract manufacturer, and India is a late arrival to a layer someone else already dominates.
Two doors, then — biosimilar ADCs and conjugation-CDMO — and both of them trail. Neither is the deal-value game. India lost that.
The access inversion, and the game India can still win
There is one number that reframes what India should even be trying to do here. AstraZeneca launched Enhertu in India in January 2024 at roughly three and a half lakh rupees per cycle, weight-based — and oncologists report that fewer than one in ten eligible Indian patients can afford it. So the modality that earned China tens of billions of dollars in licensing is, for the Indians who actually have the cancers it treats, essentially unavailable. The smart bomb exists; almost no Indian can buy it.
That is the inversion that tells India which war to fight. India lost the ADC deal-value war to China and is not getting it back. But the war that matters inside India — and across every market too poor for a three-lakh-per-cycle drug — is the affordability war, and that is the one India's biosimilar machine was built to win. The Zydus door is not the glamorous door; it will never generate an eight-billion-dollar headline. It is the door that puts an armed antibody within reach of a patient in Nagpur. If India's ADC ambition is honest, it is not "become the next China." It is "make the ADC affordable where China's licensing model never will" — the same industrialise-for-access logic that runs the whole India thesis, applied to the one modality where India already conceded the frontier.
Where it breaks
The honest bounds, and there are several, because this is the essay where India is weakest.
India's counter-position is genuinely thin. One biosimilar-ADC leader and a nascent CDMO capacity is not an industry; it is two footholds, both behind China. Any reading of this essay that turns Zydus and Syngene into an emerging Indian ADC power is overselling exactly what the essay is warning against.
The target keeps moving. The frontier of the modality is already the bispecific ADC — more than half of China's 2024 ADC deals were bispecifics like BL-B01D1 — so even the biosimilar door is chasing a class that is complexifying faster than a follower can copy it. India risks arriving, again, one generation late.
And the pessimistic outcome is a real possibility, not a strawman. It is entirely plausible that ADC value stays permanently with the Western innovators and the Chinese fast-followers, that India never advances past biosimilar and contract manufacturing, and that the affordability door turns out to be a low-margin niche rather than a strategic position. That is an argued risk, not a settled fate — but it is the honest downside, and pretending otherwise would repeat the complacency that lost India the modality in the first place.
Close
The antibody-drug conjugate is the modality this publication's doctrine was made for — proven targets, engineered payloads, a race won on optimization and cost — and it is the modality that doctrine lost. China ran India's playbook, at India's own game, on the modality most suited to it, and banked tens of billions while India shipped one biosimilar. The point of writing that down plainly is not defeatism; it is the correction the rest of the series needs. Second-mover advantage is not something a talent-rich, cost-competitive country has. It is something it must assemble — a fast regulator, real clusters, patient capital, speed — and where India assembled those, in CAR-T and in generic GLP-1, it won; where it did not, in ADCs, it lost to a neighbour who did. India's remaining game in the payload war is not the deal table. It is the affordability table — making the armed antibody reachable for the ninety per cent of Indian patients who cannot touch it today. That is a smaller ambition than China's, and a truer one. The doctrine still works. But only if you run it — and in ADCs, India learned what it costs to have the ingredients and never assemble the machine.
The fifth modality essay in the Atoms and Cells therapeutics thesis, and its deliberate counter-case: the second-mover doctrine executed better by China than by India. Receipts verified and dated: Enhertu (trastuzumab deruxtecan, Daiichi Sankyo/AstraZeneca) first FDA-approved 20 December 2019 (DESTINY-Breast01), the AZ–Daiichi collaboration signed March 2019; Kadcyla (T-DM1, Roche) approved 2013; Pfizer acquired Seagen (Padcev, Adcetris, Tivdak) for ~$43B, announced March 2023 and completed 14 December 2023, the largest biopharma M&A in years. The China out-licensing wave: BMS–SystImmune/Baili for the BL-B01D1 bispecific ADC, 11 December 2023, up to $8.4B ($800M upfront); Merck–Kelun-Biotech across 2022–23 (~$9B+ aggregate biobucks); BioNTech–DualityBio, April 2023 ($170M upfront, >$1.5B); AstraZeneca licensing LaNova's GPRC5D ADC LM-305, May 2023 (note: LaNova's Merck deal was LM-299, a PD-1/VEGF bispecific antibody, not an ADC; MediLink's ADC partners are Roche and BioNTech, not AstraZeneca). China was ~40% of global ADC out-licensing deals in 2023, and ADCs were ~56% (~$19B of ~$33B) of China's oncology out-licensing value in 2024, of which >52% were bispecifics — all figures biobucks/ceilings, not cash. China's edge: CDE trial-approval times cut from ~501 to ~87 days (a 30-working-day fast-track proposed June 2025), Shanghai/Suzhou clusters, roughly a quarter of the world's ~70 ADC-focused biotechs, and ~$890M of 2025 state payload funding — fast-follow engineering of validated targets, not de novo invention. India: no verifiable novel ADC in the clinic; Zydus Ujvira (2021) credibly the world's first ADC biosimilar (Kadcyla reference); Syngene's Bengaluru bioconjugation suite (~October 2025) and Cohance's integrated ADC services both nascent and trailing China's WuXi. ADC manufacturing is a genuine moat (HPAPI containment, sterile bioconjugation, linker-payload synthesis; <30% of innovators fully in-house). Enhertu launched in India January 2024 at ~₹3.5 lakh/cycle, with oncologists reporting <10% of eligible patients can afford it; the 1L pertuzumab combination was approved June 2026. All figures directional and point-in-time; deal values are ceilings; the "India stuck at CDMO/biosimilar" outcome is an argued risk, not a settled one. The thesis in one line: the ADC is the purest second-mover modality ever built, China ran India's own playbook and won it for tens of billions, and India's remaining game is not the deal table but the affordability table — the doctrine works only if you assemble the machine to run it.